Biopiracy: When Science Takes Without Asking

“In 1986, a US patent was granted for the ayahuasca vine, a plant sacred to Amazonian peoples who had cultivated knowledge of it for millennia. It was eventually cancelled. The patent race since then has only accelerated.”

One of The Cosmic Serpent's sharpest political arguments concerns the ethics of how Western science engages with indigenous botanical knowledge. Narby frames it as a rule embedded in shamanic tradition: the sacred is not for sale. The accumulation of personal power from spiritual knowledge is, in indigenous frameworks, the definition of black magic.

Western pharmaceutical and biotechnology industries operate by different rules. The drug discovery pipeline depends on identifying active compounds, isolating them, synthesizing modifications, and patenting the resulting intellectual property. Indigenous knowledge has served as a map for this process: which plants to study, which combinations to investigate, which compounds to isolate. The knowledge guides the research; the patent captures the value.

In 1986, US Patent 5,751,559 was granted to Loren Miller for a variety of the ayahuasca vine (Banisteriopsis caapi) he claimed to have discovered. The grant outraged indigenous organizations across the Amazon, who submitted a legal challenge arguing that the vine had been known and cultivated by their communities for millennia and could not constitute a novel invention. After a decade of legal proceedings, the patent was cancelled in 2003 on the grounds that prior art existed, the plant's use was documented in scientific literature before Miller's application.

The ayahuasca patent case is the clearest example of what critics call biopiracy: the appropriation of indigenous knowledge and genetic resources for commercial benefit without consent, benefit-sharing, or acknowledgment. The Nagoya Protocol on Access and Benefit-Sharing, which entered into force in 2014, created a legal framework for addressing this. As of 2024, 138 countries have ratified it. Enforcement remains weak.

The psychedelic patent race accelerated after 2020, with pharmaceutical companies filing patents on therapeutic protocols, dosing regimens, and molecular derivatives of classical psychedelics. The defensive patent movement, initiated by researchers at Johns Hopkins and others, attempts to prevent any single entity from monopolizing psychedelic therapy.

Sources

• Narby, The Cosmic Serpent (1998)
• WIPO, Intergovernmental Committee on GR (2024)
• Tupper, Global Networks (2009)